novonord

Novo Nordisk is a global healthcare company engaged in the discovery, development, manufacture and delivery of treatments for serious chronic diseases. Its therapeutic areas include diabetes, obesity, haemophilia, growth disorders and cardiovascular conditions. The company was founded in 1923 and employs approximately 67,000 people.

Operational scope runs from pharmaceutical research and drug discovery through biopharmaceutical manufacturing to the delivery of therapies. Technical work spans chronic disease therapies, diabetes and obesity treatments, haemophilia and growth disorder treatments, and cardiovascular treatments. The company reports serving more than 46.5 million people with its medicines and therapies.

Novo Nordisk is headquartered in Denmark and maintains affiliates in 80 countries, with operations in Belgium, Brazil, China, France, Italy, India, the United Kingdom and the United States. The stated mission is to defeat serious chronic diseases, combining scientific research with an understanding of patients' lives and an emphasis on expanding access to treatments worldwide.